Physician profile
Mackenzie Mcqueeney
NPI 1265020242
$1,612.22
in general payments reported to CMS, 2019-2025
18 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $855 · 2023: $300 · 2024: $108 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $669.87 | 2022-2025 | Zilretta, Iovera |
| Depuy Synthes Sales INC. | $182.50 | 2021-2025 | Monovisc, Orthovisc |
| Sanofi-Aventis U.S. LLC | $170.32 | 2022-2024 | |
| Amgen INC. | $99.64 | 2023-2025 | Evenity, Prolia |
| Fidia Pharma USA INC. | $60.25 | 2021-2024 | Triluron, Hymovis, Hyalgan |
| Stryker Corporation | $51.96 | 2022-2025 | Pangea |
| Smith+Nephew, INC. | $48.54 | 2022-2023 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Vertex Pharmaceuticals Incorporated | $46.48 | 2025 | |
| Medacta USA, INC. | $43.51 | 2023 | Primary Shoulder |
| Bioventus LLC | $38.90 | 2022-2025 | Durolane |
| Si-Bone, INC. | $38.49 | 2021 | |
| Pacira Therapeutics, INC. | $37.61 | 2021 | |
| Ibsa Pharma INC. | $36.27 | 2023-2024 | Tirosint, Tirosint, Licart |
| Boston Scientific Corporation | $23.46 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.58 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $16.51 | 2021 | |
| Medtronic, INC. | $15.74 | 2021 | |
| Heraeus Medical, LLC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Mcqueeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.